Browse the full directors' dealings record of JANEL CORP, a listed issuer based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Transport & Logistics sector, JANEL CORP has published 17 insider filings. Market capitalisation: €57m. The latest transaction was reported on 15 May 2026 — Acquisition. Among the most active insiders: van Kesteren Gerard. All data is openly available.
17 of 17 declarations
Janel Corp (ticker: JANL) is a U.S.-based holding company followed by investors in the small-cap and special-situation universe. The company is quoted on the OTCQX market rather than on NYSE or NASDAQ, but its profile is often analyzed through the same lens as listed industrial or logistics microcaps because of its corporate structure, acquisition-led strategy, and active capital allocation. Janel is domiciled and headquartered in the United States, with its historical roots in the New York area. From an investor standpoint, the key point is that Janel is not a single-line operating company; it is a diversified holding company with three reportable segments: Logistics, Life Sciences, and Manufacturing. Historically, the group grew out of Janel Group, founded in 1974 in Garden City, New York. The logistics business is the legacy core and remains the most recognizable part of the platform. It is a non-asset-based cargo transportation logistics manager offering freight forwarding by air, ocean, and land, customs brokerage, warehousing and distribution, trucking, and other value-added logistics services. This model is designed to serve customers that need end-to-end logistics coordination rather than pure asset ownership. The business operates across the United States and serves global customers through an international partner network. Janel’s Life Sciences segment manufactures and distributes antibodies, research reagents, and diagnostic reagents, and provides custom services to academic, nonprofit, and commercial customers. This segment reflects a move into higher-value niche markets with more specialized technical requirements. The company expanded this platform through the acquisition of ViraQuest in 2024 and Biosensis in 2025, strengthening its exposure to custom biotech services and brain-disease-related research tools. Janel’s Manufacturing segment is centered on Indco, which manufactures and distributes mixing equipment and related apparatuses for applications across different industries. In competitive terms, Janel’s strategy is differentiated by selective M&A rather than scale-based organic expansion. Management has stated that it focuses on acquiring reasonably priced businesses with strong leadership, attractive economics, and stable earnings power. Recent transactions illustrate that approach: the company added Airschott in 2024, Interlog USA in 2025, and a customs-broker/freight-forwarder customer list and related intangible assets in 2025. Another major corporate development came in October 2025, when Janel completed the sale of Janel Group LLC to Rubicon Technology in exchange for Rubicon shares. Janel Group was described as a profitable, full-service logistics provider with more than 25 locations in the United States and customers worldwide through international partners. For French-speaking investors, JANL is best viewed as a diversified U.S. microcap with a logistics foundation, a small but meaningful life-sciences footprint, and a manufacturing niche. The appeal lies in deal-making discipline and portfolio optionality; the main risks are size, integration execution, and the inherent cyclicality of freight and industrial demand.